Research ArticleAccepted Article
Relation between fatigue and ACR response in patients with psoriatic arthritis treated with TNFi therapy: a population-based cohort study
Tanja Schjødt Jørgensen, Marie Skougaard, Rebekka Lund Hansen, Christine Ballegaard, Philip Mease, Vibeke Strand, Lene Dreyer and Lars Erik Kristensen
The Journal of Rheumatology November 2020, jrheum.191107; DOI: https://doi.org/10.3899/jrheum.191107
Tanja Schjødt Jørgensen
The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; Swedish Medical Center and University of Washington, Seattle, United States; Division Immunology/Rheumatology, Stanford University, Palo Alto, United States; DANBIO Registry, Gentofte Hospital, Rigshospitalet, Hellerup, Denmark; Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, Denmark. This study was supported by a core grant from the Oak Foundation (OCAY-13-309). T. S. Jørgensen Speakers bureau: Abbvie, Roche, UCB, Novartis, Pfizer, Biogen and Eli Lilly, M. Skougaard: None declared, R. L. Hansen: None declared, C. Ballegaard Speakers bureau: Janssen Pharmaceuticals, P. Mease Consultant for: Abbvie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN, UCB, Speakers bureau: Abbvie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer, UCB, V. Strand Consultant for: Abbvie, Amgen, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Samsung, Sandoz, UCB, L. Dreyer Speakers bureau: UCB, MSD, Janssen, Eli Lilly L. E. Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, Janssen Pharmaceuticals. Corresponding author: Tanja Schjødt Jørgensen, MSc., PhD, Senior researcher, Head of Value Based Outcomes, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. Mail: tanja.schjoedt.joergensen@regioh.dk
Marie Skougaard
The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; Swedish Medical Center and University of Washington, Seattle, United States; Division Immunology/Rheumatology, Stanford University, Palo Alto, United States; DANBIO Registry, Gentofte Hospital, Rigshospitalet, Hellerup, Denmark; Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, Denmark. This study was supported by a core grant from the Oak Foundation (OCAY-13-309). T. S. Jørgensen Speakers bureau: Abbvie, Roche, UCB, Novartis, Pfizer, Biogen and Eli Lilly, M. Skougaard: None declared, R. L. Hansen: None declared, C. Ballegaard Speakers bureau: Janssen Pharmaceuticals, P. Mease Consultant for: Abbvie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN, UCB, Speakers bureau: Abbvie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer, UCB, V. Strand Consultant for: Abbvie, Amgen, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Samsung, Sandoz, UCB, L. Dreyer Speakers bureau: UCB, MSD, Janssen, Eli Lilly L. E. Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, Janssen Pharmaceuticals. Corresponding author: Tanja Schjødt Jørgensen, MSc., PhD, Senior researcher, Head of Value Based Outcomes, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. Mail: tanja.schjoedt.joergensen@regioh.dk
Rebekka Lund Hansen
The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; Swedish Medical Center and University of Washington, Seattle, United States; Division Immunology/Rheumatology, Stanford University, Palo Alto, United States; DANBIO Registry, Gentofte Hospital, Rigshospitalet, Hellerup, Denmark; Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, Denmark. This study was supported by a core grant from the Oak Foundation (OCAY-13-309). T. S. Jørgensen Speakers bureau: Abbvie, Roche, UCB, Novartis, Pfizer, Biogen and Eli Lilly, M. Skougaard: None declared, R. L. Hansen: None declared, C. Ballegaard Speakers bureau: Janssen Pharmaceuticals, P. Mease Consultant for: Abbvie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN, UCB, Speakers bureau: Abbvie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer, UCB, V. Strand Consultant for: Abbvie, Amgen, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Samsung, Sandoz, UCB, L. Dreyer Speakers bureau: UCB, MSD, Janssen, Eli Lilly L. E. Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, Janssen Pharmaceuticals. Corresponding author: Tanja Schjødt Jørgensen, MSc., PhD, Senior researcher, Head of Value Based Outcomes, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. Mail: tanja.schjoedt.joergensen@regioh.dk
Christine Ballegaard
The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; Swedish Medical Center and University of Washington, Seattle, United States; Division Immunology/Rheumatology, Stanford University, Palo Alto, United States; DANBIO Registry, Gentofte Hospital, Rigshospitalet, Hellerup, Denmark; Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, Denmark. This study was supported by a core grant from the Oak Foundation (OCAY-13-309). T. S. Jørgensen Speakers bureau: Abbvie, Roche, UCB, Novartis, Pfizer, Biogen and Eli Lilly, M. Skougaard: None declared, R. L. Hansen: None declared, C. Ballegaard Speakers bureau: Janssen Pharmaceuticals, P. Mease Consultant for: Abbvie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN, UCB, Speakers bureau: Abbvie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer, UCB, V. Strand Consultant for: Abbvie, Amgen, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Samsung, Sandoz, UCB, L. Dreyer Speakers bureau: UCB, MSD, Janssen, Eli Lilly L. E. Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, Janssen Pharmaceuticals. Corresponding author: Tanja Schjødt Jørgensen, MSc., PhD, Senior researcher, Head of Value Based Outcomes, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. Mail: tanja.schjoedt.joergensen@regioh.dk
Philip Mease
The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; Swedish Medical Center and University of Washington, Seattle, United States; Division Immunology/Rheumatology, Stanford University, Palo Alto, United States; DANBIO Registry, Gentofte Hospital, Rigshospitalet, Hellerup, Denmark; Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, Denmark. This study was supported by a core grant from the Oak Foundation (OCAY-13-309). T. S. Jørgensen Speakers bureau: Abbvie, Roche, UCB, Novartis, Pfizer, Biogen and Eli Lilly, M. Skougaard: None declared, R. L. Hansen: None declared, C. Ballegaard Speakers bureau: Janssen Pharmaceuticals, P. Mease Consultant for: Abbvie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN, UCB, Speakers bureau: Abbvie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer, UCB, V. Strand Consultant for: Abbvie, Amgen, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Samsung, Sandoz, UCB, L. Dreyer Speakers bureau: UCB, MSD, Janssen, Eli Lilly L. E. Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, Janssen Pharmaceuticals. Corresponding author: Tanja Schjødt Jørgensen, MSc., PhD, Senior researcher, Head of Value Based Outcomes, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. Mail: tanja.schjoedt.joergensen@regioh.dk
Vibeke Strand
The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; Swedish Medical Center and University of Washington, Seattle, United States; Division Immunology/Rheumatology, Stanford University, Palo Alto, United States; DANBIO Registry, Gentofte Hospital, Rigshospitalet, Hellerup, Denmark; Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, Denmark. This study was supported by a core grant from the Oak Foundation (OCAY-13-309). T. S. Jørgensen Speakers bureau: Abbvie, Roche, UCB, Novartis, Pfizer, Biogen and Eli Lilly, M. Skougaard: None declared, R. L. Hansen: None declared, C. Ballegaard Speakers bureau: Janssen Pharmaceuticals, P. Mease Consultant for: Abbvie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN, UCB, Speakers bureau: Abbvie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer, UCB, V. Strand Consultant for: Abbvie, Amgen, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Samsung, Sandoz, UCB, L. Dreyer Speakers bureau: UCB, MSD, Janssen, Eli Lilly L. E. Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, Janssen Pharmaceuticals. Corresponding author: Tanja Schjødt Jørgensen, MSc., PhD, Senior researcher, Head of Value Based Outcomes, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. Mail: tanja.schjoedt.joergensen@regioh.dk
Lene Dreyer
The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; Swedish Medical Center and University of Washington, Seattle, United States; Division Immunology/Rheumatology, Stanford University, Palo Alto, United States; DANBIO Registry, Gentofte Hospital, Rigshospitalet, Hellerup, Denmark; Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, Denmark. This study was supported by a core grant from the Oak Foundation (OCAY-13-309). T. S. Jørgensen Speakers bureau: Abbvie, Roche, UCB, Novartis, Pfizer, Biogen and Eli Lilly, M. Skougaard: None declared, R. L. Hansen: None declared, C. Ballegaard Speakers bureau: Janssen Pharmaceuticals, P. Mease Consultant for: Abbvie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN, UCB, Speakers bureau: Abbvie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer, UCB, V. Strand Consultant for: Abbvie, Amgen, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Samsung, Sandoz, UCB, L. Dreyer Speakers bureau: UCB, MSD, Janssen, Eli Lilly L. E. Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, Janssen Pharmaceuticals. Corresponding author: Tanja Schjødt Jørgensen, MSc., PhD, Senior researcher, Head of Value Based Outcomes, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. Mail: tanja.schjoedt.joergensen@regioh.dk
Lars Erik Kristensen
The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; Swedish Medical Center and University of Washington, Seattle, United States; Division Immunology/Rheumatology, Stanford University, Palo Alto, United States; DANBIO Registry, Gentofte Hospital, Rigshospitalet, Hellerup, Denmark; Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, Denmark. This study was supported by a core grant from the Oak Foundation (OCAY-13-309). T. S. Jørgensen Speakers bureau: Abbvie, Roche, UCB, Novartis, Pfizer, Biogen and Eli Lilly, M. Skougaard: None declared, R. L. Hansen: None declared, C. Ballegaard Speakers bureau: Janssen Pharmaceuticals, P. Mease Consultant for: Abbvie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN, UCB, Speakers bureau: Abbvie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer, UCB, V. Strand Consultant for: Abbvie, Amgen, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Samsung, Sandoz, UCB, L. Dreyer Speakers bureau: UCB, MSD, Janssen, Eli Lilly L. E. Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Celgene, BMS, MSD, Novartis, Eli Lilly, Janssen Pharmaceuticals. Corresponding author: Tanja Schjødt Jørgensen, MSc., PhD, Senior researcher, Head of Value Based Outcomes, The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, Road 8, Entrance 19, 2000 Frederiksberg, Denmark. Mail: tanja.schjoedt.joergensen@regioh.dk
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Relation between fatigue and ACR response in patients with psoriatic arthritis treated with TNFi therapy: a population-based cohort study
Tanja Schjødt Jørgensen, Marie Skougaard, Rebekka Lund Hansen, Christine Ballegaard, Philip Mease, Vibeke Strand, Lene Dreyer, Lars Erik Kristensen
The Journal of Rheumatology Nov 2020, jrheum.191107; DOI: 10.3899/jrheum.191107
Accepted manuscript
Relation between fatigue and ACR response in patients with psoriatic arthritis treated with TNFi therapy: a population-based cohort study
Tanja Schjødt Jørgensen, Marie Skougaard, Rebekka Lund Hansen, Christine Ballegaard, Philip Mease, Vibeke Strand, Lene Dreyer, Lars Erik Kristensen
The Journal of Rheumatology Nov 2020, jrheum.191107; DOI: 10.3899/jrheum.191107